Kiora Pharmaceuticals Inc Cash Flow Conversion Efficiency
Kiora Pharmaceuticals Inc cash flow conversion efficiency. Based on the latest financial reports, Kiora Pharmaceuticals Inc (KPRX) has a cash flow conversion efficiency ratio of -0.112x as of June 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-1.89 Million) by net assets ($16.86 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Cash Flow Conversion Efficiency of Kiora Pharmaceuticals Inc (2012–2025)
Cash flow conversion efficiency of Kiora Pharmaceuticals Inc from 2012 to 2025. This chart illustrates how Kiora Pharmaceuticals Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. View today's stock price for Kiora Pharmaceuticals Inc for real-time trading data and today's change.
Kiora Pharmaceuticals Inc Cash Flow Conversion Ratio Explained
Kiora Pharmaceuticals Inc cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.
Kiora Pharmaceuticals Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Kiora Pharmaceuticals Inc ranked by their cash flow conversion efficiency. Also see KPRX company net worth for the company's overall valuation and market capitalisation.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
STO Co. Ltd
KQ:098660
|
0.024x |
|
Ihlas Yayin Holding A.S.
IS:IHYAY
|
0.011x |
|
Modern Internasional Tbk
JK:MDRN
|
0.057x |
|
Charan Insurance Public Company Limited
BK:CHARAN
|
0.003x |
|
THG Holdings PLC
LSE:THG
|
-0.128x |
|
Humax Holdings Co. Ltd
KQ:028080
|
0.092x |
|
Equity Story Group Ltd
AU:EQS
|
0.833x |
|
Sanwil Holding SA
WAR:SNW
|
0.000x |
Annual Cash Flow Conversion Efficiency for Kiora Pharmaceuticals Inc (2012–2025)
The table below shows the annual cash flow conversion efficiency of Kiora Pharmaceuticals Inc from 2012 to 2025. Review Kiora Pharmaceuticals Inc free cash flow ratio to assess how much free cash flow the company generates relative to operating cash flow.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $16.13 Million | $-9.96 Million | -0.618x | -285.90% |
| 2024-12-31 | $25.76 Million | $8.56 Million | 0.332x | +121.24% |
| 2023-12-31 | $6.11 Million | $-9.56 Million | -1.564x | -71.12% |
| 2022-12-31 | $11.41 Million | $-10.43 Million | -0.914x | -24.84% |
| 2021-12-31 | $14.58 Million | $-10.68 Million | -0.732x | +2.63% |
| 2020-12-31 | $9.73 Million | $-7.32 Million | -0.752x | +38.92% |
| 2019-12-31 | $6.62 Million | $-8.15 Million | -1.231x | -1.46% |
| 2018-12-31 | $8.94 Million | $-10.84 Million | -1.214x | -136.15% |
| 2017-12-31 | $-1.93 Million | $-6.47 Million | 3.357x | -86.86% |
| 2016-12-31 | $-329.42K | $-8.41 Million | 25.539x | +3586.11% |
| 2015-12-31 | $6.09 Million | $-4.46 Million | -0.733x | -3184.65% |
| 2014-12-31 | $-40.03 Million | $-950.62K | 0.024x | -69.25% |
| 2013-12-31 | $-38.29 Million | $-2.96 Million | 0.077x | -48.50% |
| 2012-12-31 | $-34.81 Million | $-5.22 Million | 0.150x | -- |
About Kiora Pharmaceuticals Inc
Kiora Pharmaceuticals, Inc., a clinical-stage specialty pharmaceutical company, engages in the development and commercialization of therapies for the treatment of ophthalmic diseases. Its lead product is KIO-301, a potential vision-restoring small molecule, which is in Phase 2 clinical trials for the treatment of retinitis pigmentosa, choroideremia, and Stargardt disease. The company is also deve… Read more